Developmental delay can precede neurologic regression in early onset metachromatic leukodystrophy

IF 3.7 2区 生物学 Q2 ENDOCRINOLOGY & METABOLISM Molecular genetics and metabolism Pub Date : 2024-06-29 DOI:10.1016/j.ymgme.2024.108521
Laura Ann Adang , Samuel Groeschel , Chloe Grzyb , Russell D'Aiello , Francesco Gavazzi , Omar Sherbini , Nowa Bronner , Akshilkumar Patel , Ariel Vincent , Anjana Sevagamoorthy , Sylvia Mutua , Kayla Muirhead , Johanna Schmidt , Amy Pizzino , Emily Yu , Danielle Jin , Florian Eichler , Jamie L. Fraser , Lisa Emrick , Keith Van Haren , Maria L. Escolar
{"title":"Developmental delay can precede neurologic regression in early onset metachromatic leukodystrophy","authors":"Laura Ann Adang ,&nbsp;Samuel Groeschel ,&nbsp;Chloe Grzyb ,&nbsp;Russell D'Aiello ,&nbsp;Francesco Gavazzi ,&nbsp;Omar Sherbini ,&nbsp;Nowa Bronner ,&nbsp;Akshilkumar Patel ,&nbsp;Ariel Vincent ,&nbsp;Anjana Sevagamoorthy ,&nbsp;Sylvia Mutua ,&nbsp;Kayla Muirhead ,&nbsp;Johanna Schmidt ,&nbsp;Amy Pizzino ,&nbsp;Emily Yu ,&nbsp;Danielle Jin ,&nbsp;Florian Eichler ,&nbsp;Jamie L. Fraser ,&nbsp;Lisa Emrick ,&nbsp;Keith Van Haren ,&nbsp;Maria L. Escolar","doi":"10.1016/j.ymgme.2024.108521","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>Metachromatic leukodystrophy (MLD) is a rare neurodegenerative disorder. Emerging therapies are most effective in the presymptomatic phase, and thus defining this window is critical. We hypothesize that early development delay may precede developmental plateau. With the advent of presymptomatic screening platforms and transformative therapies, it is essential to define the onset of neurologic disease.</p></div><div><h3>Methods</h3><p>The specific ages of gain and loss of developmental milestones were captured from the medical records of individuals affected by MLD. Milestone acquisition was characterized as: on target (obtained before the age limit of 90th percentile plus 2 standard deviations compared to a normative dataset), delayed (obtained after 90th percentile plus 2 standard deviations), or plateau (skills never gained). Regression was defined as the age at which skills were lost. LI-MLD was defined by age at onset before 2.5 years.</p></div><div><h3>Results</h3><p>Across an international cohort, 351 subjects were included (<em>n</em> = 194 LI-MLD subcohort). The median age at presentation of the LI-MLD cohort was 1.4 years (25th–75th %ile: 1.0–1.5). Within the LI-MLD cohort, 75/194 (39%) had developmental delay (or plateau) prior to MLD clinical presentation. Among the LI-MLD cohort with a minimum of 1.5 years of follow-up (<em>n</em> = 187), 73 (39.0%) subjects never attained independent ambulation. Within LI-MLD + delay subcohort, the median time between first missed milestone target to MLD decline was 0.60 years (maximum distance from delay to onset: 1.9 years).</p></div><div><h3>Interpretation</h3><p>Early developmental delay precedes regression in a subset of children affected by LI-MLD, defining the onset of neurologic dysfunction earlier than previously appreciated. The use of realworld data prior to diagnosis revealed an early deviation from typical development. Close monitoring for early developmental delay in presymptomatic individuals may help in earlier diagnosis with important consequences for treatment decisions.</p></div>","PeriodicalId":18937,"journal":{"name":"Molecular genetics and metabolism","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular genetics and metabolism","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1096719224004050","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

Metachromatic leukodystrophy (MLD) is a rare neurodegenerative disorder. Emerging therapies are most effective in the presymptomatic phase, and thus defining this window is critical. We hypothesize that early development delay may precede developmental plateau. With the advent of presymptomatic screening platforms and transformative therapies, it is essential to define the onset of neurologic disease.

Methods

The specific ages of gain and loss of developmental milestones were captured from the medical records of individuals affected by MLD. Milestone acquisition was characterized as: on target (obtained before the age limit of 90th percentile plus 2 standard deviations compared to a normative dataset), delayed (obtained after 90th percentile plus 2 standard deviations), or plateau (skills never gained). Regression was defined as the age at which skills were lost. LI-MLD was defined by age at onset before 2.5 years.

Results

Across an international cohort, 351 subjects were included (n = 194 LI-MLD subcohort). The median age at presentation of the LI-MLD cohort was 1.4 years (25th–75th %ile: 1.0–1.5). Within the LI-MLD cohort, 75/194 (39%) had developmental delay (or plateau) prior to MLD clinical presentation. Among the LI-MLD cohort with a minimum of 1.5 years of follow-up (n = 187), 73 (39.0%) subjects never attained independent ambulation. Within LI-MLD + delay subcohort, the median time between first missed milestone target to MLD decline was 0.60 years (maximum distance from delay to onset: 1.9 years).

Interpretation

Early developmental delay precedes regression in a subset of children affected by LI-MLD, defining the onset of neurologic dysfunction earlier than previously appreciated. The use of realworld data prior to diagnosis revealed an early deviation from typical development. Close monitoring for early developmental delay in presymptomatic individuals may help in earlier diagnosis with important consequences for treatment decisions.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
早发性变色性白质营养不良症患者在神经系统退化之前可能会出现发育迟缓。
目的:变色性白质营养不良症(MLD)是一种罕见的神经退行性疾病。新出现的治疗方法在无症状期最为有效,因此确定这一窗口期至关重要。我们假设,早期发育迟缓可能先于发育平稳期。随着无症状筛查平台和变革性疗法的出现,确定神经系统疾病的发病时间至关重要:方法:我们从多发性硬化症患者的病历中获取了发育里程碑获得和丧失的具体年龄。里程碑获得的特征为:达标(与常模数据集相比,在第90百分位数加2个标准差的年龄限制之前获得)、延迟(在第90百分位数加2个标准差之后获得)或高原(从未获得技能)。回归是指技能丧失的年龄。LI-MLD以2.5岁之前的发病年龄来定义:在一个国际队列中,共纳入了 351 名受试者(n = 194 LI-MLD 亚队列)。LI-MLD队列的发病年龄中位数为1.4岁(第25-75百分位数:1.0-1.5岁)。在LI-MLD队列中,75/194(39%)人在MLD临床表现前有发育迟缓(或停滞)。在随访至少1.5年的LI-MLD队列中(n = 187),有73人(39.0%)从未实现独立行走。在LI-MLD+发育迟缓亚群中,从首次错过里程碑目标到MLD下降的中位时间为0.60年(从发育迟缓到发病的最大距离:1.9年):早期发育迟缓早于LI-MLD患儿的发育退步,其神经功能障碍的发病时间早于以往的认识。在诊断前使用真实世界的数据显示了早期典型发育偏差。对无症状个体的早期发育迟缓进行密切监测,可能有助于早期诊断,并对治疗决策产生重要影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Molecular genetics and metabolism
Molecular genetics and metabolism 生物-生化与分子生物学
CiteScore
5.90
自引率
7.90%
发文量
621
审稿时长
34 days
期刊介绍: Molecular Genetics and Metabolism contributes to the understanding of the metabolic and molecular basis of disease. This peer reviewed journal publishes articles describing investigations that use the tools of biochemical genetics and molecular genetics for studies of normal and disease states in humans and animal models.
期刊最新文献
Sensitivity of transferrin isoform analysis for PMM2-CDG Assessing carnosinase 1 activity for diagnosing congenital disorders of glycosylation Treatment of congenital disorders of glycosylation: An overview CIC variants and folinic acid-responsive seizures Characterisation of infantile cardiomyopathy in Alström syndrome using ALMS1 knockout induced pluripotent stem cell derived cardiomyocyte model
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1